Recent Updates
Recently added Catalysts

PIKA rabies vaccine

Phase 2

Rabies | Monoclonal antibody | Infectious Disease |LakeShore Biopharma Co., Ltd|Last Updated: Nov 8, 2016

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDDMC
Total Trials2
Total Enrollment163

FDA Designations

No designations recorded

Clinical trial landscape

PIKA rabies vaccine · 2 trials · 1 indication

Phase 2 1Phase 1 1
NCT02956421Efficacy and Safety of a PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated RegimenRabies
COMPLETED126 Analytics
PHASE2COMPLETED
Efficacy and Safety of a PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen
RabiesUnlock trial analytics

Study Endpoints

Primary Endpoints

Titer level of Rabies Virus Neutralizing Antibody (RVNA) from serum at accelerated regimen
42 days

Evaluation of the accelerated regimen is studied to check if the levels of anti-rabies antibodies (serum RVNA titer) will be better than a classic course with control commercialized vaccine.

Identification of any adverse events for all the treatment groups
42 days

Assessment of safety based on the identification of any adverse events for all the treatment groups, Group A, Group B and Group C through to the end of the study at day 42.

Titer level of Rabies Virus Neutralizing Antibody (RVNA) from serum at day 14 and 42 after the first injection
Day 14 and Day 42

To analyze the titer level of RVNA from serum at day 14 and 42 after the first injection and with RVNA titer meeting the 0.5 IU(International units) /ml World Health Organization (WHO) requirement

Secondary Endpoints

Number of subjects in Group B who has higher RVNA titre level on Day 7 when compared to classic course.
Day 7
Detectable specific T cell mediated immune response on day 7 or day 14 and 42
Day 7, Day 14 and Day 42
Number of subjects in Group C who has higher RVNA titre level on Day 7 or Day 14 when compared to classic course.
Day 7 and Day 14
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
RABIPUR®ACTIVE_COMPARATORComparator vaccine RABIPUR® Healthy volunteers received rabies vaccination intramuscularly on days 0,3,7 and 14
PIKA Rabies vaccineEXPERIMENTALPIKA Rabies vaccine with an accelerated regimen Healthy volunteers received rabies vaccination intramuscularly on days 0 (2 Doses), 3 (2 Doses), and day 7 (1 Dose)
Group AACTIVE_COMPARATORComparator vaccine RABIPUR® Healthy volunteers received rabies vaccination intramuscularly on days 0,3,7 and 14
Group BEXPERIMENTALPIKA Rabies vaccine Healthy volunteers received rabies vaccination intramuscularly on days 0,3,7 and 14
Group CEXPERIMENTALPIKA Rabies vaccine with an accelerated regimen Healthy volunteers received rabies vaccination intramuscularly on days 0 (2 Doses), 3 (2 Doses), and day 7 (1 Dose)

Interventions

NameTypeDescription
RABIPUR®BIOLOGICALBiological rabies vaccine
PIKA rabies vaccineBIOLOGICALBiological rabies vaccine
PIKA rabies vaccine with an accelerated regimenBIOLOGICALBiological rabies vaccine
Unlock Study Design Details

Eligibility Criteria

Age Range21 Years to 65 Years
SexALL
Healthy VolunteersYes
Study Sites2

Inclusion Criteria: * Informed consent form has been signed and dated * Able to attend all scheduled visits and comply with all trial procedures. * Never received rabies vaccine before. * Refrain from blood donation during the course of the study. * Able to attend all scheduled visits and comply wi...

Countries:Singapore
Unlock Eligibility Criteria